Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase IIa study of HX009 + IN10018 with or without standard chemotherapy in advanced solid tumors
CTR20244298Phase 2Active
- Sponsor
- Hansi Bio
- Start
- Jan 2025
- Modality
- Small Molecules, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of HX009, ifebemtinib in melanoma, biliary cancer, Nonhematologic neoplasms, sponsored by Hansi Bio. Started Jan 2025; status: active.
02
Drugs
HX009ifebemtinib
03
Conditions
melanomabiliary cancerNonhematologic neoplasms
Beyond the preview
Go deeper on CTR20244298.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20244298.